Related articles

• Randomized Controlled Trial

  Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.

  Ann. Oncol. 2020 Nov 1; 31 (11): 1536-1544.

• Multicenter Study

  Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b...

  Lancet Oncol. 2020 Mar 1; 21 (3): 373-386.

• Randomized Controlled Trial

  Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.

  Cancer. 2020 Jan 15; 126 (2): 373-380.

Show more related articles...